Biomerica(BMRA) Newsfilter·2025-01-16 13:19Core Insights - Biomerica, Inc. has received approval for its Fortel® Prostate Specific Antigen (PSA) Screening Test from the United Arab Emirates Ministry of Health and Prevention, marking a significant step in early prostate cancer detection [1][3]. Product Overview - The Fortel® PSA Screening Test is a rapid diagnostic tool that delivers results in just 10 minutes using a finger-prick blood sample, allowing for early detection of prostate cancer and related conditions [2][4]. - The test has shown high performance metrics, including 100% sensitivity, 95% specificity, and 97.5% accuracy in studies, validating its effectiveness [7]. Market Context - Prostate cancer is the second most common cancer among men globally, with 1.4 million new cases and 375,000 deaths reported in 2020, highlighting the urgent need for effective screening solutions [5]. - The disease is increasingly recognized as a public health concern in the Middle East, where there is a gap in comprehensive studies and awareness [5]. Strategic Initiatives - Biomerica aims to expand its presence in the Middle East, building on previous successes with other diagnostic tests, and has established partnerships with distributors to enhance accessibility to early cancer detection [3][6]. - The company is committed to providing affordable and accurate diagnostic tools to improve health outcomes in the region [6].